Boehringer Ingelheim and OSE Immunotherapeutics Expand Partnership to Develop Therapies for Cancer and Cardio-Renal-Metabolic (CRM) Diseases
Shots:
- The previous partnership between BI & OSE focused on the development of OSE-172 (now BI 770371), jointly, targeting myeloid lineage cells
- The expansion states BI 765063 & BI 770371, under P-I trial for advanced solid tumors, will also be developed for CRM diseases with their P-II study expected later in 2024 plus an asset acquisition of new preclinical product targeting immune-cell activation using OSE’s cis-targeting anti-PD1/cytokine platform
- OSE will obtain $14.64M upfront & $18.97M milestones on purchasing the preclinical asset; for BI 765063 & BI 770371, the two agreed on a partial royalty buy-out with a one-time $27.4M payment. BI gains an option for another buy-out during development, resulting in a one-time payment & sales milestone. The $1.19B development, regulatory & sales milestones remain unchanged
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- AbbVie and OSE Immunotherapeutics Join Forces for the Development of OSE-230 to Treat Chronic Inflammation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
